CLEARREAD +CONFIRM

by RIVERAIN TECHNOLOGIES  · Based in United States →Artificial Intelligence. Real Results.™
Critical Care Radiology

Not publicly available
Regulatory Status Disclosed

Overview

CLEARREAD +CONFIRM is part of Riverain Technologies’ ClearRead Xray suite, an AI-powered solution designed to enhance the interpretation of chest X-ray images. This specific application is engineered to generate an enhanced, secondary digital radiographic image of the chest, primarily to facilitate the confirmation and improved visibility of lines and tubes. By optimizing the visual quality of chest X-rays, including portable images, CLEARREAD +CONFIRM helps radiologists read up to 19% faster without compromising accuracy or confidence.

The ClearRead Xray suite, leveraging unique suppression technology and Clear Visual Intelligence™, provides an unimpaired view of the chest, revealing actionable data for the correct and rapid detection of cardiothoracic diseases. It is a workflow-friendly tool that integrates seamlessly into existing PACS/RIS environments, offering a cost-effective alternative to dual-energy subtraction without additional radiation dose or changes to existing imaging protocols for patients.

Riverain Technologies, founded in 2004, is a medical software innovator focused on revolutionizing early disease detection through artificial intelligence in cardiothoracic imaging. Their FDA-cleared ClearRead solutions are utilized by healthcare institutions globally to improve diagnostic accuracy, streamline radiologist workflow, and contribute to better patient outcomes, particularly in lung cancer screening and diagnosis.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Enhanced visibility of lines and tubes on chest X-rays
  • Reduces reading time for portable chest X-rays by approximately 19%
  • Maintains radiologist accuracy and confidence
  • Generates an enhanced, secondary digital radiographic image
  • Aids in critical care device confirmation
  • No additional radiation dose or changes to existing imaging protocols
  • Seamless integration into existing imaging workflows (PACS/RIS)
  • Optimizes portable chest X-rays for optimal and efficient visibility
  • Utilizes unique suppression technology for unimpaired chest view

Use Cases

  • Confirmation of lines and tubes in chest radiographs
  • Improving efficiency in reading portable chest X-rays
  • Enhancing diagnostic confidence for critical care device placement
  • General chest X-ray interpretation where lines/tubes are present
  • Streamlining radiologist workflow in high-volume environments

What Physicians Need to Know

DICOM Support & Standards
ClearRead applications generate adjunctive DICOM images and content, seamlessly integrating with existing PACS. ClearRead Xray - Detect accepts DICOM input and outputs DICOM Secondary Capture. ClearRead Xray Pneumothorax receives and delivers images via DICOM protocol over a standard IEEE 802.3 network connection.
PACS Integration Method
The solution integrates seamlessly into the existing PACS workflow as an additional series within the patient study, eliminating the need for a separate application viewer. Processed images are automatically inserted into the patient's file for instant access on existing PACS review stations.
Reading Room Workflow Impact
ClearRead +Confirm improves the clarity of conventional chest X-ray images, aiding in the confirmation of medical device placement. The broader ClearRead suite has been shown to reduce reading times for radiologists (e.g., 20-36% reduction for CT reads) and improve the detection of pulmonary nodules, enhancing visualization of clinically relevant findings and easing cognitive load. It supports concurrent reading.
AI Model Architecture (deep learning approach)
The technology is powered by machine learning and advanced modeling, utilizing deep learning. It employs unique suppression technology, such as bone suppression for X-ray images (ClearRead +Confirm) and vessel suppression for CT, to remove obscuring structures. Riverain developed the capability to create synthetic nodules for training its software.
FDA Clearance Pathway (510k/De Novo)
ClearRead +Confirm received FDA 510(k) clearance. Riverain Technologies has multiple FDA-cleared products, including ClearRead CT, which also received 510(k) clearance.
Supported Modalities (CT/MRI/X-ray/US)
ClearRead +Confirm is designed for conventional chest X-ray images. The broader ClearRead suite supports chest CT and X-ray modalities. There is no information indicating support for MRI or Ultrasound.
Sensitivity & Specificity Data
For ClearRead +Confirm (X-ray), bone-suppressed images showed a 17% improvement in the detection of previously missed nodules. For ClearRead CT, studies demonstrated a 21% greater nodule detection rate and a 29% reduction in missed actionable nodules. One study on LDCT images reported a mean per-nodule sensitivity increase from 63% to 79% with software use, with per-person specificity remaining stable (81% with vs. 77% without).
RSNA/ACR Validation
Studies involving Riverain's ClearRead CT have been presented at the Radiological Society of North America (RSNA) annual meeting, including in 2024. Duke University Medical Center, an American College of Radiology (ACR) designated center for Lung Cancer Screening, has deployed Riverain's ClearRead CT software.
Physician Tip

Leverage ClearRead +Confirm for enhanced visualization of medical device placement on chest X-rays, particularly in challenging cases where ribs and clavicles may obscure visibility. For CT, utilize the vessel suppression and nodule detection features to improve reading efficiency and accuracy, especially for small or subtle pulmonary nodules. Integrate the AI-generated series into your standard hanging protocols for a seamless workflow, allowing for concurrent reading and comparison with original images without needing a separate viewer. Be aware that the software provides adjunctive information and should be used in conjunction with the original images for diagnosis. Consider its potential for opportunistic screening of coronary artery disease with CAC scoring on ungated CT scans.

Riverain's ClearRead solutions are designed for seamless integration into existing PACS environments, delivering processed images as an additional series. The system is enterprise-ready, compatible with CT scans from various manufacturers and acquisition protocols, and can be deployed on off-the-shelf hardware or virtual machine environments. It supports integration via AI marketplaces or distribution platforms like CARPL.ai, and does not typically require new hardware or customized tuning to specific devices. Ensure your PACS can display adjunctive DICOM images effectively for optimal workflow.

Details

Category Radiology & Imaging AI
Pricing Not publicly available
DeploymentOn-premise (server, virtual machine) or cloud
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

CLEARREAD +CONFIRM (K123526) was cleared by the FDA on December 27, 2012. It is intended to generate an enhanced, secondary digital radiographic image of the chest to facilitate confirmation of line/tubes, providing improved visibility of these structures as adjunctive information.

Integrations
EHR Not specified
Specialties Critical Care, Radiology

What the Web Says

Riverain Technologies' CLEARREAD +CONFIRM is an AI-powered imaging software designed to enhance the detection of lung abnormalities in chest X-rays and CT scans by suppressing vessels and bone structures. Physicians generally report that the technology improves reading efficiency and accuracy, leading to earlier detection of diseases like lung cancer. The software integrates with existing PACS systems, aiming to streamline workflow without requiring new hardware or disrupting current processes.

Overall: Positive

Strengths

  • Improved detection of lung nodules, especially small ones (u22642 mm).
  • Reduced reading times for radiologists and residents.
  • Enhanced visualization of the chest by suppressing vessels and bone.
  • Seamless integration with existing PACS and hospital workflows.
  • FDA-cleared and CE marked.
  • Potential for earlier intervention and improved patient outcomes.

Limitations

  • No specific cons were found in the provided search results from physicians, healthcare IT, or tech reviewers regarding CLEARREAD +CONFIRM.
  • General concerns about AI in radiology include potential over-reliance and the need for further research on the clinical significance of certain findings.
  • Some general G2 reviews for other 'Clear' products mention inconsistency or erratic behavior.

Based on reviews from: 3DR Labs, Riverain Technologies, Imaging Wire, G2, Capterra

Last updated: 2026-07-19

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate CLEARREAD +CONFIRM

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Riverain Technologies
What role is AI playing in Northeast Ohio hospitals? Experts weigh in.
This article discusses the role of AI in Northeast Ohio hospitals, featuring insights from experts, likely including Riverain Technologies' contributions to healthcare AI.
2026-03
JobsOhio
Riverain Technologies Expanding to Drive Growth and Advance Health Tech Innovation
Riverain Technologies announced its expansion, creating 48 new jobs in Miamisburg, Ohio, to further its mission of transforming radiology through AI tools like ClearReadu2122 for improved diagnostic accuracy and patient outcomes.
2026-01
Riverain Technologies
VIDA Partners with Riverain Technologies to Extend Best-of-Breed AI Imaging for Life Sciences
VIDA and Riverain Technologies have partnered to integrate their AI imaging solutions, aiming to enhance life sciences research and applications.
2025-11
Riverain Technologies
deepc Enriches Enterprise Health AI Portfolio with Riverain Technologies' ClearReadu2122 solutions on deepcOSu00ae
deepc has integrated Riverain Technologies' ClearReadu2122 solutions into its deepcOSu00ae platform, expanding its enterprise health AI portfolio to improve diagnostic capabilities.
2025-11
Riverain Technologies
Study Shows ClearReadu2122 CT CAC for Incidental Coronary Artery Calcification Highly Effective on Ungated CT Exams
A study demonstrated the high effectiveness of ClearReadu2122 CT CAC in detecting incidental coronary artery calcification on ungated CT exams, highlighting its potential for opportunistic screening of heart disease.
2025-11
Riverain Technologies
Bialogics and Riverain Set the New Benchmark for AI Adoption
Bialogics and Riverain Technologies have collaborated to establish new standards for AI adoption in healthcare, focusing on integrating AI into clinical workflows.
2025-11
DAIC
Riverain Technologies Launches New FDA-Cleared Technology, Expands Globally
Riverain Technologies announced its global expansion across eight countries and the launch of new FDA-cleared technology that extends ClearRead CT functionality to provide coronary artery calcium scores for ungated scans.
2025-02

Videos

Product demos, reviews, and walkthroughs for CLEARREAD +CONFIRM.

View all on YouTube

Frequently Asked Questions

CLEARREAD +CONFIRM is designed for seamless integration into any digital radiology department, offering universal connectivity with existing PACS systems. It processes portable chest X-rays immediately after capture, creating enhanced images that radiologists can toggle with the original for review, without requiring additional imaging equipment.
CLEARREAD +CONFIRM optimizes the visual quality of chest X-rays, improving the conspicuity of lines and tubes, and aiding in the detection of lung abnormalities like nodules and pneumothorax. This can lead to increased reading efficiency, with studies showing radiologists reading up to 19% faster without compromising accuracy.
CLEARREAD +CONFIRM is FDA-cleared in the United States and holds the CE Mark in Europe, indicating its compliance with health, safety, and environmental protection standards. It also conforms to DICOM standards for digital communications of medical information.
While specific details on data privacy directly from Riverain Technologies for CLEARREAD +CONFIRM are limited in the provided information, the ClearRead suite, when integrated into platforms like deepcOS, emphasizes patient safety and data privacy by design. Generally, such medical AI systems are expected to comply with relevant healthcare data protection regulations and integrate securely with existing IT infrastructure.
Yes, the market offers several alternatives and competitors to ClearRead Xray, which includes Confirm, such as Qure.ai's qLC-Suite for lung nodule detection, and various PACS solutions like ProtonPACS that integrate advanced viewing tools. Other general medical imaging software like 3D Slicer and Invivo5 also exist, though their direct comparison to ClearRead +Confirm's specific functionalities may vary.
Pricing information for Riverain Technologies' ClearRead Xray Detect, part of the ClearRead Xray suite, indicates models such as a one-time license fee or a subscription based on the number of analyses. It is often deployed as a software solution that can be applied to every X-ray device in a facility for one fixed cost, suggesting an enterprise-wide licensing approach.
CLEARREAD +CONFIRM is intended as an aid and does not replace the physician's interpretation. The system has specific input constraints, and invalid input can cause it to reject a series for processing, meaning no result will be returned. Physicians must still exercise their clinical judgment despite the enhanced visibility provided.
No, CLEARREAD +CONFIRM is explicitly intended to be used as an aid only after the physician has performed an initial interpretation of the radiograph. It enhances image clarity and highlights potential areas of concern, but the final diagnostic responsibility and interpretation remain with the physician.

Related Tools

OCTA
OCTA
Clinical Decision Support & Reference
OCTA Flow is an AI-powered platform that assists ophthalmologists in analyzing Optical Coherence Tomography Angiography (OCTA) scans to enhance diagnostic accuracy and efficiency.
Smart Reporting
Smart Reporting
Clinical Decision Support & Reference
A German health tech startup uses artificial intelligence to cut time spent on medical reports and improve patient care. Founded by a radiologist, Smart Reporting aims to standardize reporting and minimize documentation time, addressing the looming threat of physician shortage in Europe.
RetiVue EntireEye Imaging
RetiVue, LLC
Ophthalmology AI
RetiVue manufactures ultrawidefield retinal cameras with automatic image capture, aiming to aid in the early documentation of eye disease and prevent blindness. Their EntireEye Imaging System offers both desktop and portable options, providing true color, high-detail images with a wide field of view for patients from infancy to adulthood.
LesionQuant
CorTechs Labs
Neurology AI
LesionQuant, an FDA-approved AI product by CorTechs Labs, is particularly useful for patients with multiple sclerosis. It provides brain structure data and quantifies the number, size, and location of lesions, comparing them to prior studies.
Augmentiqs Augmented Reality Microscope (ARM)
Augmentiqs Medical Ltd.
Clinical Decision Support & Reference
Augmentiqs integrates augmented reality into existing microscopes, providing real-time access to digital pathology software, AI algorithms, and telepathology capabilities directly within the microscope's field of view.
AI Optics Sentinel Camera
AI Optics
Ophthalmology AI
AI Optics' Sentinel Camera is an FDA 510(k)-cleared handheld retinal imaging system designed to capture high-quality images for retinal disease screening, with future plans for integrated AI-based screening software for diabetic retinopathy, glaucoma, and macular degeneration.

See all Radiology & Imaging AI tools →

More from Riverain Technologies

ClearRead CT
RIVERAIN TECHNOLOGIES
Cardiology AI
ClearRead CT is an FDA-cleared AI suite by Riverain Technologies for cardiothoracic health, enhancing pulmonary nodule detection and coronary artery calcification analysis in CT scans. It improves diagnostic accuracy, reduces reading times, and streamlines radiology workflows through advanced AI and vessel suppression technology.
ClearRead CT CAC
Riverain Technologies
Cardiology AI
ClearRead CT CAC by Riverain Technologies is an AI-powered software that enables opportunistic screening for coronary artery calcification (CAC) by accurately detecting, quantifying, and reporting Agatston scores from routine, ungated, non-contrast chest CT scans.
ClearRead Xray Pneumothorax
Riverain Technologies
Radiology & Imaging AI
ClearRead Xray Pneumothorax is an AI-driven tool by Riverain Technologies that provides triage notification for suspected pneumothorax (5mm or larger) on adult chest X-rays, aiming for early detection and improved radiologist efficiency.
DELTAVIEW MODEL
Riverain Technologies
Oncology AI
DELTAVIEW MODEL, by Riverain Technologies (formerly Riverain Medical Group), is an AI-driven medical imaging software for temporal comparison of chest X-rays, designed to detect subtle changes like early-stage lung cancer nodules through bone suppression and image subtraction technology.

View company profile →

Suggest an Edit → | Last Verified: 2026-04-19 | First Added: 2026-04-19
AI Tool Finder
AI-powered search. Results may not be comprehensive.